Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16433691 | 0.92 | DGAT2 (0.39) | DGAT2CYP2C9P2RX3CDK2PTGER4 | |
| SCHEMBL416953 | 0.87 | DGAT2 (0.43) | DGAT2CYP2C9P2RX3PHGDHPTGER4 | |
| SCHEMBL417788 | 0.85 | DGAT2 (0.45) | DGAT2CYP2C9P2RX3PHGDHPTGER4 | |
| SCHEMBL16433529 | 0.79 | DGAT2 (0.35) | DGAT2CYP2C9P2RX3PTGER4EGLN1 | |
| SCHEMBL16433695 | 0.77 | DGAT2 (0.37) | DGAT2CYP2C9P2RX3PTGER4EGLN1 | |
| SCHEMBL415320 | 0.72 | ALDH1A1 (0.51) | CDK2KDM4ELMNAMAPTMEN1 | |
| SCHEMBL13092889 | 0.72 | P2RX3 (0.65) | DGAT2CYP2C9P2RX3PHGDHPTGER4 | |
| SCHEMBL415486 | 0.72 | MAPT (0.64) | CDK2KDM4ELMNAMAPTMEN1 | |
| SCHEMBL3070767 | 0.71 | P2RX3 (0.64) | DGAT2CYP2C9P2RX3PHGDHPTGER4 | |
| SCHEMBL3070764 | 0.71 | P2RX3 (0.64) | DGAT2CYP2C9P2RX3PHGDHPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2410858-B1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8946231-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | DGAT2 4151/4885CYP2C9 3902/4885P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.